National Institutes of Health says COVID-19 patients should not take hydroxychloroquine
April 22, 2020Research and Development COVID-19, coronavirus, hydroxychloroquine
Experts at the US National Institutes of Health (NIH) have drafted treatment guidelines for the use of hydroxychloroquine in COVID-19 …
Bayer’s Vitrakvi becomes first tumour-agnostic therapy approved by NICE for NHS patients with NTRK fusion+ cancer
April 21, 2020Manufacturing and Production, Sales and Marketing Bayer, Cancer, NICE, UK, Vitrakvi, tumour agnostic
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) has just been recommended by NICE in the treatment of advanced neurotrophic tyrosine receptor …
Deaths in England and Wales hit 20 year high due to COVID-19 fatalities
April 21, 2020Manufacturing and Production COVID-19, COVID-19 UK, coronavirus, coronavirus uk
Deaths in England and Wales have hit a 20 year high, boosted by fatalities from the COVID-19 coronavirus. The Office …
Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint
April 21, 2020Manufacturing and Production BMS, Bristol-Myers Squibb, Exelixis, bristol myers squibb
Bristol Myers Squibb and Exelixis have announced that the Phase 3 trial investigating the combination of Opdivo (nivolumab) and Cabometyx …
Five-year data supports early treatment with Novartis’ Mayzent in secondary progressive multiple sclerosis
April 21, 2020Manufacturing and Production, Research and Development Mayzent, Novartis, pharma
Novartis has pulled back the curtain on five-year data from an extension trial for its sphingosine 1-phosphate receptor modulator Mayzent …
FDA to take steps to ease shortages of drugs for COVID-19 patients on ventilators
April 21, 2020Manufacturing and Production COVID-19, Ventilators, coronavirus
The FDA is to allow small compound pharmacies to fill the shortages of medicines needed for patients with COVID-19 who …
How the intended role of generic medicines is being undermined in America
April 20, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Drug pricing, US, feature, generic medicines, generics
The introduction of a generic medicine should, in theory, incentivise companies to lower the price of the original drug, creating healthy …
Novartis to sponsor large clinical trial of hydroxychloroquine in COVID-19 patients
April 20, 2020Sales and Marketing COVID19 Coronavirus, coronavirus, covid19
The FDA and Novartis have agreed to move forward with a Phase 3 clinical trial to evaluate the effectiveness of …
Gilead’s remdesivir significantly reduces COVID-19 symptoms in rhesus monkeys in NIH trial
April 20, 2020Business Services, Medical Communications, Sales and Marketing COVID-19, Gilead, National Institutes of Health, coronavirus, remdesivir
A study from the National Institutes of Health has shed more light on the efficacy of Gilead’s promising antiviral therapy …
English COVID-19 cases to be tracked by ethnicity
April 20, 2020Sales and Marketing African-Americans, BAME, COVID-19, coronavirus
Cases of coronavirus are set to be tracked by ethnicity in England following an announced government review. The governments have …
Incyte’s Pemazyre becomes FDA’s first and only approved unresectable, advanced cholangiocarcinoma treatment
April 20, 2020Sales and Marketing FDA, Incyte, pharma
The FDA has approved the United States’ first and only treatment for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma, …
Hydroxychloroquine fails COVID-19 clinical trial in France
April 20, 2020Sales and Marketing COVID-19, chloroquine, coronavirus, hydroxychloroquine
The malaria treatment hydroxychloroquine is facing further scrutiny as a coronavirus treatment after failed trials in France. The most recent …
FDA cautions that drug reviews will be slower due to COVID-19
April 17, 2020Medical Communications COVID-19, FDA, coronavirus
The FDA has warned that they may not be able to sustain its current levels of timely reviews and approvals …
US Government’s BARDA to fund Moderna’s coronavirus vaccine by $483m
April 17, 2020Medical Communications, Research and Development BARDA, COVID-19, Moderna, coronavirus, pharma
Moderna has secured $483 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), to drive development and …
Top Ten most popular articles on Pharmafile.com this week
April 17, 2020Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, coronavirus, top 10
Hydroxychloroquine dominates the news as the potential COVID-19 treatment has gone through various trials. A Chinese study showed that the …
Leaked data show Gilead’s remdesivir allows severe COVID-19 patients to be discharged after six days
April 17, 2020Medical Communications, Research and Development COVID-19, Gilead, coronavirus, remdesivir
The clinical benefit of Gilead’s promising antiviral therapy Remdesivir has been touted in the treatment of severe cases of COVID-19 …
Governor of Minnesota signs emergency bill for insulin access
April 17, 2020Medical Communications diabetes, insulin, insulin copays, medical insurance
Minnesota Governor Tim Walz has signed legislation to provide a one-time, 30-day supply of insulin for eligible residents in urgent …
Clinical trial suggests new schizophrenia drug could reduce symptoms
April 16, 2020Business Services D2, clinical trials, schizophrenia
Results from a newly published clinical trial suggest that a new compound could treat a broad range of schizophrenia symptoms. …
FDA approves UroGen’s Jelmyto as first therapy for low-grade upper tract urothelial cancer
April 16, 2020Sales and Marketing Cancer, FDA, Jelmyto, UroGen Pharma, pharma, urothelial cancer
The FDA has moved to authorise UroGen Pharma’s Jelmyto (mitomycin gel) in the US for the treatment of low-grade upper …
New Chinese study shows Hydroxychloroquine does not speed up COVID-19 recovery
April 16, 2020Business Services COVID-19, chloroquine, coronavirus, hydroxychloroquine
The anti-malaria drug hydroxychloroquine does not speed up recovery from COVID-19, according to a new Chinese study. The study was …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
